Who Took Money? Psychiatric Diagnosis, Pharmaceutical Markets, and the Financial Architecture of the DSM

This investigation examines the relationship between psychiatric diagnostic authority, commercial financial relationships, institutional pharmaceutical support, regulatory use of diagnostic categories, and downstream market consequences across the modern DSM era. It does not begin from the premise that pharmaceutical companies wrote the DSM or that financial conflicts prove diagnostic manipulation. Instead, it asks a narrower question: what financial and institutional architecture can be documented around persons and organizations exercising meaningful authority over psychiatric diagnosis, and what conclusions can that architecture support without crossing from evidence into accusation? The analysis uses a six-edition authority census, published panel-level conflict studies, person-level forensic reconstructions, an APA institutional-support ledger, a payer-product-diagnosis map, commercial-stakes records, a public-source DSM-to-trial-to-FDA-to-market reconstruction, and comparative population analyses. Missing records are treated as unknown rather than zero; personal remuneration, institutional support, equity or intellectual property, and company revenue are kept separate; and later financial relationships are not backdated into earlier decision periods. The record supports repeated high-authority financial conflicts in DSM-IV and DSM-5, recurring pharmaceutical or corporate support of APA educational and meeting programming, and a downstream mechanism by which DSM-defined populations can become operational in clinical trials and regulatory pathways. The pediatric ANCHOR/Seroquel case provides an unusually reconstructable example of that mechanism, but does not establish that DSM criteria were created for Seroquel. Population analyses show heterogeneous dynamics rather than a single universal curve: depression treatment expanded rapidly and then decelerated while long-duration antidepressant exposure accumulated; ADHD shows both diagnosed-prevalence growth and criterion-dependent eligibility; bipolar youth diagnosis shows a rapid diagnostic-expansion pattern; schizophrenia provides a cautious diagnosis-versus-treatment-market comparator; and anxiety remains too heterogeneous for a clean shared trajectory. The strongest system-level inference supported by the current record is Structural Alignment: descriptive coexistence of recurrent high-authority conflicts, institutional commercial support, downstream diagnostic/regulatory pathways, and commercial stakes. Functional Capture—a stronger hypothesis that commercial interests systematically shape how the diagnostic system functions or its outputs—is SUGGESTIVE but not established. Deliberate pharmaceutical control of particular DSM decisions remains unsupported because the required decision-maker bridges are generally absent.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-17
DOI
https://doi.org/10.5281/zenodo.23286794
Primary Topic
Pharmaceutical industry and healthcare
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Who Took Money? Psychiatric Diagnosis, Pharmaceutical Markets, and the Financial Architecture of the DSM

Dale Farley
Zenodo (CERN European Organization for Nuclear Research)
Pharmaceutical industry and healthcare
preprint

Who Took Money? Psychiatric Diagnosis, Pharmaceutical Markets, and the Financial Architecture of the DSM

Dale Farley
preprint en

Abstract

This investigation examines the relationship between psychiatric diagnostic authority, commercial financial relationships, institutional pharmaceutical support, regulatory use of diagnostic categories, and downstream market consequences across the modern DSM era. It does not begin from the premise that pharmaceutical companies wrote the DSM or that financial conflicts prove diagnostic manipulation. Instead, it asks a narrower question: what financial and institutional architecture can be documented around persons and organizations exercising meaningful authority over psychiatric diagnosis, and what conclusions can that architecture support without crossing from evidence into accusation? The analysis uses a six-edition authority census, published panel-level conflict studies, person-level forensic reconstructions, an APA institutional-support ledger, a payer-product-diagnosis map, commercial-stakes records, a public-source DSM-to-trial-to-FDA-to-market reconstruction, and comparative population analyses. Missing records are treated as unknown rather than zero; personal remuneration, institutional support, equity or intellectual property, and company revenue are kept separate; and later financial relationships are not backdated into earlier decision periods. The record supports repeated high-authority financial conflicts in DSM-IV and DSM-5, recurring pharmaceutical or corporate support of APA educational and meeting programming, and a downstream mechanism by which DSM-defined populations can become operational in clinical trials and regulatory pathways. The pediatric ANCHOR/Seroquel case provides an unusually reconstructable example of that mechanism, but does not establish that DSM criteria were created for Seroquel. Population analyses show heterogeneous dynamics rather than a single universal curve: depression treatment expanded rapidly and then decelerated while long-duration antidepressant exposure accumulated; ADHD shows both diagnosed-prevalence growth and criterion-dependent eligibility; bipolar youth diagnosis shows a rapid diagnostic-expansion pattern; schizophrenia provides a cautious diagnosis-versus-treatment-market comparator; and anxiety remains too heterogeneous for a clean shared trajectory. The strongest system-level inference supported by the current record is Structural Alignment: descriptive coexistence of recurrent high-authority conflicts, institutional commercial support, downstream diagnostic/regulatory pathways, and commercial stakes. Functional Capture—a stronger hypothesis that commercial interests systematically shape how the diagnostic system functions or its outputs—is SUGGESTIVE but not established. Deliberate pharmaceutical control of particular DSM decisions remains unsupported because the required decision-maker bridges are generally absent.

Zenodo (CERN European Organization for Nuclear Research)
Pharmaceutical industry and healthcare
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon